Cardialen is developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm MINNEAPOLIS, October 10, 2018-- Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will be used to advance Cardialen’s clinical program with further human testing of its unpinning termination (UPT) therapy and begin development of an implantable device.